Booth: 301, 507
AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.
Envolve Pharmacy Solutions provides total drug management that combines the systems, tools and expertise of a PBM with the capabilities and experience of a comprehensive specialty pharmacy, AcariaHealth, to provide a full spectrum of pharmacy benefit management services that are tailored to each of our plan sponsor partners.
Accredo is a full-service specialty pharmacy dedicated to the treatment of rare and complex conditions. Our comprehensive therapy management programs engage trained pharmacists, nurses, reimbursement specialists, and patient care representatives who provide enhanced support services to patients, their families and healthcare professionals.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases, including lysosomal acid lipase deficiency (LAL-D), through the innovation, development and commercialization of life-changing therapies.
Alfa Wassermann clinical chemistry systems use liquid, ready-to-use reagents, providing an inexpensive alternative to dry chemistry. Alfa Wassermann offers a compact, cost-effective, easy-to-use, innovative benchtop blood chemistry analyzer to maximize research success by quickly and cost effectively transforming in-vivo drug safety and efficacy screens.
Allergan plc (NYSE: AGN), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. For more information, visit Allergan’s website at www.Allergan.com.
Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, and hepatic infectious diseases with unmet need. Alnylam’s investigational medicines include four late-stage product candidates, with one under regulatory review. www.alnylam.com.
The Alpha-1 Foundation is a not-for-profit organization that is dedicated to providing the leadership and resources that will result in increased research, improved health, worldwide detection, and a cure for Alpha-1 Antitrypsin Deficiency.
Founded in 1976, the American Liver Foundation (ALF) is the nation’s leading nonprofit health organization for people living with liver disease. We are a nationwide network of staff and volunteers that provides awareness, outreach, education and patient support services to educate the public about liver health and to improve the lives of individuals and their families affected by liver disease.
Today APASL is one of the leading associations based on investigation and treatment of liver diseases in the world and the largest scientific body that upholds the standards and profession, research and create improved treatment methods for millions of liver patients particularly in the entire Asia Pacific Region.
A non-profit scientific association founded in 1968, whose main objective is to promote and disseminate the study of Hepatology in Latin America, through training and the exchange of scientific knowledge and experiences, to reduce current gaps in the world.
The Mexican Hepatology Association is a leading organization involved in the advancement of science and practice of hepatology, promoting better care for patients with liver and biliary diseases. It is involved in the innovation and development of new therapeutic options and is committed to the training of specialists.
Audentes Therapeutics is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases. We have four product candidates in development including AT342 for the treatment of Crigler-Najjar. We are committed to forging strong relationships with the patient, research and medical communities.
The Autoimmune Hepatitis Association (AIHA) is a nonprofit that offers education and support for patients and families affected by autoimmune hepatitis. The AIHA hosts a biennial patient conference (next one is July 2019 in Indianapolis) and a social media community that connects patients with one another and with research opportunities.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power.
BioMatrix offers nationwide specialty pharmacy services and digital health technology for chronic health conditions. Our family of companies unites leaders to improve health and empower patients to experience a higher quality of life. BioMatrix includes: BiologicTx, Decillion Healthcare, Elwyn Pharmacy Group, Factor Support Network, Matrix Health, and Medex Biocare.
BioPredictive offers diagnostic and prognostic blood tests for liver diseases. Over a million tests performed worldwide. BioPredictive’s diagnosis and prognosis tests (FiboTest-ActiTest, FibroMax, HCV-GenoFibroTest including IL28b ) are available on line at www.biopredictive.com FibroTest App (free) including ElastoFibroTest and DAAFibroTest available on iPhone and Android.
Blue Faery: The Adrienne Wilson Liver Cancer Association is devoted to fighting primary liver cancer. Founded in Burbank, California, with a satellite location in Birmingham, Alabama, Blue Faery’s mission is to prevent, treat and cure primary liver cancer through research, education and advocacy. For more information, visit www.bluefaery.org.
Boston Scientific is dedicated to transforming patient lives by developing diagnostic and therapeutic devices that support less invasive, more efficient procedures for a variety of GI conditions. Through innovation and partnership, we are advancing important clinical research, supporting education programs and helping healthcare institutions deliver high quality healthcare while managing costs.
BriovaRx is a leading specialty pharmacy services company dedicated to helping administer and deliver high-quality, cost-effective specialty pharmacy care. BriovaRx combines technology, data and expertise to provide educational resources, 24/7 pharmacy support and trusted advice to the individuals, caregivers and care teams we serve.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Visit BMS at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.
Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization whose mission is to find a cure and improve the quality of life for those affected by bile duct cancer.
The Cochrane Hepato-Biliary Group (CHBG), part of Cochrane, is a non-profit, non-industry funded international clinical research group with 2300 members. In issue 4, 2018 of The Cochrane Library, we published 343 peer-reviewed protocols and 211 systematic reviews. A CHBG Register with RCTs and CCTs is maintained in The Cochrane Library.
The Community Liver Alliance connects patients to health care providers and services; creates and conducts screenings and educational programs; supports local youth transplant camp; promotes awareness of liver wellness; offers a patient assistance program, funds local research and meets with local, state, and federal policy makers to initiate positive change.
Covance is the world’s most comprehensive drug development company. LabCorp, our parent company, is a market leader in diagnostics with strength in the management of infectious diseases. Together, we offer a single-source solution for drug development and treatment of acute and chronic infections. Together, we improve health and improve lives.
CTI is a global, privately held, full-service CRO with a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. We specialize in the unique challenges associated with hepatic populations, and our therapeutic expertise is a driving force enabling us to successfully design/manage drug development programs in hepatology.
Our commitment to helping patients and their physicians manage complex drug therapies by delivering expert individualized care and unmatched, multi-channel access has made us one of the leading specialty pharmacies in the country. We provide a full-range of pharmaceutical care, dispensing the latest FDA-approved medications.
At CymaBay, we are committed to improving the lives of patients with liver and other chronic diseases by developing and providing access to innovative therapies. We are dedicated to enhancing the quality of healthcare by addressing the complex needs of patients, caregivers and communities and advancing medical knowledge.
See what’s new in liver injury biomarkers for NASH, AH, and DILI research at Booth 601. Cytokeratin/Keratin 18 (CK18/K18) is an important biomarker of hepatocyte cell death. Explore RUO M30/M65 ELISAs for measuring hepatocyte apoptosis/necrosis non-invasively. Diapharma offers additional RUO assays for liver injury, including HA, α-GST, and Collagen IV.
Hepaxa™ / Hepaxa™PD are medical foods for dietary management of early-stage NAFLD patients (adults or adolescents aged 10-18). Hepaxa™ is a very specific EPA/DHA ratio shown to reduce steatosis; and 99% of liver-related impurities (POP, PCB) have been filtered/removed. Distributed by DIEM Labs, LLC and developed by BASF/ Pronova (Norway).
Discover monumental developments in science and medicine at Digestive Disease Week (DDW) 2018. DDW is the premier event for gastroenterology, hepatology, endoscopy and gastrointestinal surgery professionals. Visit us to learn about liver programming at DDW. Join us June 2–5, 2018, in Washington DC.
DILIsym Services, Inc. has developed the DILIsym® modeling software and the NAFLDsym® modeling software to increase the efficiency of drug development for the pharmaceutical industry by informing key decisions. DILIsym Services, Inc. makes this software available to pharmaceutical companies in addition to performing services projects with the modeling software.
Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re dedicated to bringing brilliant medicine to market.
Dynavax leverages the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the US for the prevention of hepatitis B in adults.
Echosens is the world’s leading provider of non-invasive, point of care medical devices dedicated to the liver. Our FibroScan® devices are the first to be FDA cleared as an aid for managing patients with liver disease. Echosens also offers the FibroView™ connectivity solution as well as the FibroMeter™ blood test.
As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of commercial focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Enanta Pharmaceuticals is a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases. Enanta’s research and development efforts, are currently focused on the following disease targets: non-alcoholic steatohepatitis, primary biliary cholangitis, respiratory syncytial virus and hepatitis B virus.
Since 1966, EASL has continued to grow into a major European Association with international influence dedicated to liver research. It has over 4,400 members and its International Liver Congress™ unites over 10,000 liver experts. EASL supports clinical trials and research to the benefit of patients world-wide.
Exelixis, Inc. (Nasdaq:EXEL) is committed to the discovery, development and commercialization of treatments with the potential to improve outcomes for people with cancer. Exelixis is focused on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, which has shown clinical activity in more than 20 forms of cancer.
Gastroenterology & Endoscopy News, a monthly newspaper, provides smart, objective and comprehensive clinical news reporting from international, national and regional gastroenterology meetings. It also features in-depth original articles, educational reviews, CME monographs and monthly commentary from celebrated gastroenterologists.
Gastroenterology & Hepatology is a monthly, independent peer-reviewed journal that is mailed to all US gastroenterologists and hepatologists (16,700+). Content is directed by strong input of experts in the field. G&H contains thought leader-driven review articles, clinical case studies with expert commentary, and advances columns featuring engaging interviews with experts on current issues in IBD, IBS, GERD, Hepatitis and Endoscopy.
GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases, where there is still considerable unmet need.
GI Supply offers the RenovaRP Paracentesis Management System to improve all aspects of large volume paracentesis. The RenovaRP System enhances patient safety and satisfaction, is easy on staff, and is cost effective. The system is highly portable and can be used virtually anywhere, supporting efficient procedures all around.
Booth: 313, 219, 521, 526
Gilead Sciences, Inc., founded in 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead's portfolio includes treatments for HIV/AIDS, hepatitis, respiratory and cardiovascular conditions, cancer and inflammation. Gilead is one of the world’s largest biopharmaceutical companies, with approximately 5,500 employees across four continents.
Gore Medical Products Division engineers devices that treat a range of cardiovascular and other health conditions. Gore builds on its legacy of improving patient outcomes through research, education, and quality initiatives. Product performance, ease of use, and quality of service provide sustainable cost savings for physicians, hospitals, and insurers.
We’re reporting LIVE. Follow what’s trending at Healio.com/GI. See what your peers are reading online – in print. Stop by our booth and pick up your free issue of Healio Gastroenterology – a unique peer-tested news magazine. Also see HCV Next. Go to Healio.com/Register.
The HealthWell Foundation is an independent non-profit dedicated to reducing financial barriers to care for underinsured Americans with chronic and life-altering medical conditions. HealthWell offers a financial lifeline to adults and children who desperately need critical medical treatments but can't afford them by assisting with their cost-sharing obligations. Learn more: www.HealthWellFoundation.org.
HEPATIQ is image analysis software that quantifies liver disease severity. It measures liver function, volume, and portal hypertension. Infections, alcohol and fat buildup lead to fibrosis which the liver mitigates by regenerating. Measuring fibrosis is not enough as it is the residual liver function that determines disease outcomes.
Hong Kong Humanity & Health Medical Group, composed with H&H Research Center; H&H Medical Center (GI & Liver Center, Digestive Endoscopy Centre, Hepatitis C Diagnosis & Treatment Center cooperated with Beijing 302 Hospital of PLA); Explicit Global Medical Group Limited (Medical Diagnostic and Health Assessment Center, Medical Laboratory Center). Visit us at www.hnhmgl.com
Humedics has developed a breath test based diagnostic system for measuring functional liver capacity – the LiMAx test. The system comprises a CE-marked medical device, a breath mask and a intravenously administered diagnostic drug. The system has not yet been evaluated and cleared by the FDA and is therefore currently not marketed in the United States.
INDIGO Biosciences, Inc. has established itself as the industry-leading provider of assay kits and screening services focused on nuclear receptors. With the world’s largest portfolio, INDIGO products and services help customers improve the speed to data, accuracy, ease of use, and cost efficiency of their drug discovery research.
Booth: 227, 513
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA has approximately 55,000 employees worldwide. Learn more at iqvia.com.
Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. For more information visit www.merck.com.
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) exhibit highlights the importance of alcohol research, prevention, and treatment for maintaining health. The NIAAA booth features publications appropriate for the public, research findings for professionals and policy makers, and research grant opportunities available for biomedical and social science researchers.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis products are sold in approximately 155 countries around the world.
OraSure Technologies manufactures oral fluid devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for HIV and HCV antibodies, influenza antigens, testing solutions for detecting drugs of abuse, and oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.
Organovo develops dynamic, multicellular, 3D bioprinted human tissues that closely mimic native architecture and function for the advancement of preclinical safety testing, disease modeling, ADME, and therapeutic applications. Available through our NovoView™ Preclinical Services, ExVive™ 3D Bioprinted Liver and Kidney Tissues model human biology for effective translation to the clinic.
Our mission is to unite people diagnosed with Primary Biliary Cholangitis (formerly known as Primary Biliary Cirrhosis), which is a progressive chronic liver disease. Our organization helps PBC patients, their care givers, friends and families cope with PBC and improve the quality of their lives through education and support.
Perspectum Diagnostics combines state-of-the-art digital imaging technologies and innovative software to empower the medical community through Magnetic Resonance Imaging (MRI). Our LiverMultiScan™ and MRCP+ ™ Quantitative Analysis Services have been developed to aide new approaches to liver disease management, enabling new therapies and supporting earlier and more accurate diagnosis of disease.
Philips is a leading health technology company focused on improving people’s health and enabling better outcomes. Philips EPIQ ultrasound system features the Ultimate Ultrasound Liver solution to non-invasively assess liver disease, including ElastQ Imaging, a real-time, large Region of Interest (ROI), color-coded quantitative assessment of tissue stiffness using shear wave elastography.
PhoenixBio produces the PXB-Mouse®, the world’s most widely used humanized liver chimeric mouse model, for pre-clinical development. With a liver consisting up to 95% human hepatocytes, the PXB-Mouse® offers reproducible human translatability in the fields of DMPK/Tox, HBV/HCV, NASH/NAFLD and Gene Editing/Oligonucleotide Therapeutics, saving time and costs in pre-clinical development.
The Pittsburgh Liver Research Center provides a platform to enhance scientific interactions and collaborations among scientists and physicians and support research by providing innovative cores, clinical component, pilot funding and enrichment program. Gene Expression: The Journal of Liver Research, publishes articles on all aspects of basic and translational liver research.
Plexision develops and markets cell-based tests for personalized disease management and drug development for the Immunocompromized host. The company's first product, Pleximmune, is FDA-approved to predict rejection in children with liver or intestine transplantation. Plexision's products and services are offered from its CLIA-approved, GLP- and GMP-compliant reference laboratory.
Promethera Biosciences is a global innovator in liver therapeutics whose mission is to enable patients to overcome acute and chronic liver diseases by developing cell and antibody technologies. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties.
Prometheus is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. We are primarily focused on the detection, diagnosis and treatment of disorders within the fields of gastroenterology and oncology.
ProSciento is a full scope clinical R&D services provider, exclusively focused on NASH, diabetes and obesity. The company is widely recognized for quality and scientific excellence, extensive experience, and scalable R&D services model – combining deep therapeutic area expertise, strategic planning, and operational execution from preclinical to phase III readiness.
PSC Partners Seeking a Cure provides education and support to PSC patients, families and caregivers, and raises funds to research causes, treatments and cures for Primary Sclerosing Cholangitis. PSC Partners has awarded $3 million in research grants, has a growing patient registry, and holds annual conferences for patients and caregivers.
Resoundant, Inc. produces magnetic resonance elastrography, MRE, technology that is available for new and existing MRI scanners manufactured by Philips, GE and Siemens. MRE was developed by Dr. Richard Ehman and his team at the Mayo Clinic. There are nearly 900 systems installed around the world. www.resoundant.com
Retrophin is a biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options.
For over 20 years, Salix Pharmaceuticals, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. has been committed to providing solutions for the management of many chronic and debilitating conditions. Salix currently markets products to U.S. healthcare providers in the areas of gastroenterology, hepatology, internal medicine, primary care, infectious disease, and allergy/immunology.
Samsara Sciences is dedicated to the provision of high-quality primary human liver and kidney cells. We specialize in non-parenchymal cells of the liver isolated from a spectrum of healthy and diseased donors. Each lot of cells comes with extensive phenotypical characterization and comprehensive histopathologic assessment of the tissue of origin.
Sanyal Biotechnology is a contract research organization specializing in pre-clinical small animal model screening of drugs. We have developed a proprietary mouse model, the DIAMONDTM mouse, that develops NAFLD and NASH solely as a result of Western Diet.
Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a drug discovery-based pharmaceutical company founded in Osaka, Japan 139 years ago. Our focus is on developing the best possible medicines that address unmet medical needs and help patients and their families worldwide.
SuperSonic Imagine is an innovative ultrasound imaging company that has developed a revolutionary ultrasound system: the Aixplorer®. Aixplorer is the only system on the market with a real time ShearWave™ Elastography exam. The exam takes as little as 60 seconds and provides image guided quantification of liver tissue stiffness.
The NASH Education ProgramTM is a healthcare initiative driven in collaboration with an independent and international scientific committee, aimed at producing and disseminating essential medical knowledge about NASH (Non-Alcoholic Steatohepatitis). The objective is to develop disease awareness activities targeting multiple audiences (physicians, patients and families) and address unmet information needs.
Since the program's inception in 1981, UPMC Transplant Services has been a pioneer in the development and refinement of new transplant procedures. UPMC is committed to reducing waiting list deaths through robust living-donor kidney and living-donor liver transplant programs, as well as other innovative methods to expand the donor pool.
Virology Education is a leading provider of innovative scientific and educational programs worldwide, with over 20 years of experience and a wide network of experts. Our programs provide platforms for scientific exchange, education and knowledge-sharing tailored to the needs of healthcare professionals in the fields of virology and liver disease.
Vital Therapies is a late clinical stage biotechnology company developing an investigational human hepatic cell-based therapy targeting the treatment of acute forms of liver failure. Our research suggests our VTL C3A cells produce beneficial proteins both spontaneously and in response to compounds found in the patient’s plasma.
Wako Diagnostics offers biomarkers AFP-L3 (lectin-reactive alpha-fetoprotein) and DCP (des-gamma-carboxy prothrombin) to aid in the early detection of hepatocellular carcinoma (HCC) in at-risk patients, increasing the possibility of timely application of curative therapies and improved patient outcomes. Both blood tests are 510(k)-cleared, CMS reimbursed, and available at major reference laboratories.
Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments, and individuals increase the academic and professional impact of their work.
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101, is initially being developed as a novel treatment for Wilson Disease and has been evaluated in a Phase 2 clinical study.
WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.